Recombinant Bacteriocin leucocin-C

What is leucocin C and what are its basic properties?

Leucocin C is a class IIa bacteriocin (pediocin-like bacteriocin) originally produced by Leuconostoc carnosum 4010, a protective culture used for meat products . It has a molecular mass of approximately 4.6 kDa and demonstrates potent antilisterial activity .

The mature leucocin C peptide is characterized by:

• A conserved YGNGV motif in the N-terminal region, which is a signature sequence of class IIa bacteriocins

• A calculated molecular weight of 4.6 kDa based on amino acid sequence

• Heat stability and resistance to various environmental conditions

• Strong inhibitory activity against Listeria monocytogenes and other Gram-positive bacteria

Class IIa bacteriocins like leucocin C are characterized by their distinctive mode of action on bacterial cell membranes, typically causing membrane permeabilization and dissipation of the proton motive force (PMF) in sensitive cells .

What is the genetic organization of the leucocin C gene cluster?

The leucocin C gene cluster in Leuconostoc carnosum 4010 has been localized to a large plasmid distinct from the one harboring the leucocin A genes . The genetic organization includes:

• lecC: The structural gene encoding the leucocin C precursor, which contains a 72-bp signal sequence

• lecI: The immunity gene encoding a 97-amino acid immunity protein that protects the producer cell

• lecXTS: Another operon encoding an ABC transporter (LecT) and an accessory protein (LecS) required for secretion

Unlike the leucocin A operon in L. carnosum 4010, which only contains structural and immunity genes (lcaAB) without transporter genes, the leucocin C cluster consists of two intact operons . The lecXTS operon shares 97% identity with the leucocin A transporter operon lcaECD of Leuconostoc gelidum .

How can leucocin C be heterologously expressed in laboratory settings?

Several successful expression systems have been developed for recombinant production of leucocin C:

Expression in Saccharomyces boulardii:

• Using the plasmid pSF-TEF1-TPI1-Blast as the expression vector

• A synthetic DNA fragment containing the yeast secretion signal followed by the mature leucocin C sequence is inserted

• The TEF1 promoter (one of the strongest known for protein expression in S. cerevisiae) drives expression

• Blasticidin S resistance serves as the selection marker

Expression in Lactococcus lactis:

• The mature part of the lecC gene is fused with the signal sequence of usp45 in the secretion vector pLEB690

• Expression can be achieved through either:

  • Plasmid-based expression (N8-p-lecCI)

  • Homologous recombination method (N8-r-lecCI) for enhanced stability

• L. lactis efficiently secretes leucocin C as shown by inhibition zones against L. monocytogenes

Verification of expression typically includes:

• Antimicrobial activity assays against indicator strains

• SDS-PAGE analysis

• Gel overlay assays with sensitive indicator strains

What are the common methods for detecting and quantifying recombinant leucocin C?

Several methods have been established for detecting and quantifying recombinant leucocin C:

Antimicrobial activity assays:

• Agar diffusion assay: Supernatants are spotted on agar plates seeded with indicator strains (typically L. monocytogenes)

• Zone of inhibition measurements correlate with bacteriocin concentration

Protein detection methods:

• Tricine-SDS-PAGE: Typically reveals leucocin C as a band between 4.6 and 10 kDa

• Gel overlay assay: After electrophoresis, the gel is placed on agar plates seeded with the indicator strain, showing inhibition zones corresponding to active bacteriocin

Chromatographic methods:

• Reverse-phase HPLC for purification and quantification

• Size exclusion chromatography for molecular size verification

Mass spectrometry:

• MALDI-TOF MS to confirm the molecular weight and identity of the purified peptide

What challenges exist in heterologous expression of leucocin C, and how can they be overcome?

Researchers face several challenges when working with recombinant leucocin C:

Genetic stability issues:

• Plasmid instability in the absence of selection pressure

• Solution: Homologous recombination-based expression (e.g., N8-r-lecCI in L. lactis) provides greater stability without antibiotic selection pressure

Post-translational modifications:

• Ensuring correct disulfide bond formation (if present) in the recombinant peptide

• Solution: Co-expression with accessory proteins that have chaperone-like activity to ensure correct disulfide bonding, similar to what has been observed with pediocin PA-1

Secretion efficiency:

• The choice of signal sequence significantly impacts secretion efficiency

• Solution: Using well-characterized secretion signals such as the usp45 signal sequence for expression in L. lactis or appropriate yeast secretion signals for S. boulardii

Expression levels:

• Balancing expression levels to avoid toxicity to the host

• Solution: Selection of appropriate promoters and optimization of culture conditions; for example, using the TEF1 promoter for expression in S. boulardii or optimizing induction conditions in bacterial systems

Host cell compatibility:

• Ensuring the host doesn't degrade or inactivate the recombinant bacteriocin

• Solution: Selecting hosts with demonstrated compatibility with class IIa bacteriocins, such as L. lactis or S. boulardii

How does co-expression of leucocin C with other bacteriocins affect antimicrobial efficacy?

The co-expression of leucocin C with other bacteriocins, particularly those with different modes of action, can lead to enhanced antimicrobial activity:

Nisin Z and leucocin C co-expression:

• A recombinant L. lactis strain (N8-r-lecCI) co-expressing nisin Z and leucocin C has been developed

• This strain demonstrates enhanced antimicrobial activity compared to the parental strain

• The co-expression strategy provides effective inhibition against:

  • Listeria monocytogenes (strong inhibition)

  • Staphylococcus aureus (strong inhibition)

  • Salmonella enterica serovar Enteritidis (moderate inhibition)

  • Escherichia coli (moderate inhibition)

Synergistic effects with EDTA:

• The antibacterial activity of L. lactis N8-r-lecCI supernatant is enhanced in the presence of low concentrations of EDTA

• Scanning electron microscopy has revealed more significant cellular morphology changes in L. monocytogenes when treated with a mixture of EDTA and the co-expression supernatant

• This combination has demonstrated practical effectiveness in pasteurized milk through time-kill assays

The enhanced efficacy is attributed to:

• Different targets and modes of action between nisin (primarily targeting lipid II) and leucocin C (targeting the mannose phosphotransferase system)

• Potential synergistic membrane destabilization effects

• Greater difficulty for target bacteria to develop resistance against multiple antimicrobial mechanisms simultaneously

What are the latest methodologies for purification of recombinant leucocin C?

Purification of recombinant leucocin C typically involves multiple chromatographic steps:

Initial concentration:

• Ammonium sulfate precipitation of culture supernatants

• Centrifugation and filtration to remove cells and debris

Chromatographic purification strategies:

• Ion-exchange chromatography: Cationic exchange resins like SP-Sepharose are effective due to the positive charge of leucocin C at physiological pH

• Hydrophobic interaction chromatography: Exploits the hydrophobic properties of bacteriocins

• Reverse-phase HPLC: Often used as a final purification step with C18 columns

• Size exclusion chromatography: For separation based on molecular size

Alternative purification approaches:

• Direct adsorption/desorption from producer cells: Bacteriocins can be adsorbed to producer cells at neutral pH and desorbed under acidic conditions

• Sep-Pak C18 cartridges as an intermediate purification step

Verification methods:

• SDS-PAGE with specific staining methods

• Gel overlay assays with indicator organisms

• Mass spectrometry to confirm purity and molecular weight

• N-terminal sequencing for identity confirmation

Purification yields and activity can be optimized by manipulating the expression conditions:

• pH control during fermentation

• Temperature optimization

• Oxygen levels (e.g., lower oxygen levels have been found favorable for production of active pediocin PA-1 by C. glutamicum in batch fermentations)

How can functional immunity genes be identified and characterized in recombinant systems?

The identification and characterization of immunity genes associated with bacteriocins like leucocin C are crucial for designing effective expression systems. The following methodologies have been employed:

Genetic identification:

• Analyzing the operon structure surrounding the bacteriocin structural gene

• PCR-based methods and sequencing to identify potential immunity genes

• Comparative genomics to identify homology with known immunity proteins

Functional verification:

• Expressing the putative immunity gene (e.g., lecI) in sensitive indicator strains

• For example, lecI was expressed in L. monocytogenes, resulting in reduced sensitivity to leucocin C compared to the vector control strain, thus confirming its immunity function

Characterization of immunity proteins:

• The immunity protein for leucocin C (LecI) is 97 amino acids in length

• It shares 48% homology with immunity proteins of sakacin P and listeriocin

• Immunity proteins typically function by:

  • Directly interacting with the bacteriocin

  • Interacting with the bacteriocin receptor in the cell membrane

  • Preventing pore formation or bacteriocin insertion into the membrane

The successful incorporation of immunity genes in expression systems ensures:

• Protection of the host producer cell from self-toxicity

• Maintenance of stable production over time

• Higher yields of the recombinant bacteriocin

What genetic modifications can enhance the stability or activity of recombinant leucocin C?

Several genetic modifications have been explored or can be considered to improve recombinant leucocin C's properties:

Signal sequence optimization:

• Using efficient secretion signals like usp45 for expression in L. lactis

• Codon optimization of signal sequences for the specific host

Promoter selection:

• Strong constitutive promoters like TEF1 for yeast expression systems

• Inducible promoters for controlled expression in bacterial systems

Genetic stabilization:

• Genomic integration (homologous recombination) for stable expression without selection pressure

• Documented in L. lactis through the replacement of N8GL37-38 genes with lecCI genes

Potential structure-based modifications:

• Modifications in the C-terminal region might affect target specificity

• Site-directed mutagenesis based on structure-function analyses of related bacteriocins

• Hybrid bacteriocins combining domains from different class IIa bacteriocins may exhibit altered specificity profiles

Comparison with related bacteriocins:
Studies with pediocin-like bacteriocins suggest that:

• N-terminal mutations may affect the range of activity

• Mutations in the mid-region (residues 8-19) can significantly impact activity

• The GXXXG motif may be involved in specific interactions between peptide components in two-component bacteriocins

How can recombinant leucocin C be applied in food safety research?

Recombinant leucocin C shows promising applications in food safety research:

Biopreservation studies:

• The strong antilisterial activity makes recombinant leucocin C valuable for controlling L. monocytogenes in food products

• Time-kill assays in pasteurized milk have verified its practical effectiveness

Development of bioactive packaging:

• Incorporation of purified recombinant leucocin C or producer organisms into food packaging materials

• Testing stability and activity under various storage conditions

Combination strategies:

• Co-application with other antimicrobials like nisin has shown enhanced effects

• Synergistic effects with EDTA have been demonstrated, suggesting potential for combined preservation approaches

Specificity and resistance studies:

• Investigation of target specificity against various foodborne pathogens

• Monitoring for development of resistance in repeated exposure experiments

What new variants of leucocin C have been identified, and how do they compare?

Several variants of leucocin C have been identified with distinct properties:

Leucocin C-607:

• Produced by Leuconostoc pseudomesenteroides 607 isolated from persimmon fruit

• Differs from the original leucocin C by only one amino acid residue

• Molecular size of 4623.05 Da

• Partial N-terminal amino acid sequence: NH₂-KNYGNGVHxTKKGxS, containing the YGNGV motif characteristic of class IIa bacteriocins

Leucocyclicin C:

• Produced by Leuconostoc lactis strain APC 3969

• A novel variant of the circular bacteriocin leucocyclicin Q

• Comprises 61 amino acids with a molecular mass of 6,081.44 Da

• Has a broad spectrum of activity, including inhibition of Clostridium perfringens

• Exhibits protease resistance and high stability against thermal and pH stresses

• Has a minimum inhibitory concentration (MIC) of 3.288 µM against C. perfringens

• Genetic cluster comprises ten genes versus the five genes described for leucocyclicin Q

Leucocin C-TA33a:

• Produced by Leuconostoc mesenteroides TA33a

• Predicted molecular mass of 4598 Da

• Inhibits Listeria and other lactic acid bacteria

• Part of a multiple bacteriocin production system, along with leucocin A-TA33a and leucocin B-TA33a

Comparative studies suggest that production of leucocin A-, B-, and C-type bacteriocins is widespread among Leuconostoc/Weissella strains .

What methods are employed to study the mode of action of recombinant leucocin C?

Understanding the mode of action of recombinant leucocin C involves several experimental approaches:

Membrane permeabilization assays:

• Fluorescent dye leakage assays using artificial liposomes

• Measurement of membrane potential changes in target cells

• Assessment of intracellular ATP leakage

Microscopy techniques:

• Scanning electron microscopy to visualize morphological changes in target cells

• Confocal microscopy with fluorescently labeled bacteriocins to track localization

• Atomic force microscopy to observe membrane disruption at the nanoscale

Receptor identification studies:

• As a class IIa bacteriocin, leucocin C likely targets the mannose phosphotransferase system (Man-PTS)

• Generation of resistant mutants and characterization of mutations in the Man-PTS

• Competition assays with other class IIa bacteriocins

Molecular dynamics simulations:

• In silico modeling of leucocin C interaction with bacterial membranes

• Structure-function relationship studies based on computational models

Based on studies of related bacteriocins, class IIa bacteriocins like leucocin C typically act on sensitive cells by:

• Initial binding to the Man-PTS receptor

• Insertion into the cytoplasmic membrane

• Formation of poration complexes or ionic channels

• Causing reduction or dissipation of the proton motive force (PMF)

• Eventually leading to cell death

What are the latest advancements in optimizing recombinant bacteriocin production systems?

Recent advances in optimizing recombinant bacteriocin production systems include:

Novel expression hosts:

• Corynebacterium glutamicum has been identified as a suitable production host for pediocin PA-1

• C. glutamicum CR099 shows resistance to high concentrations of pediocin PA-1 and does not inactivate the bacteriocin

• This approach could potentially be adapted for leucocin C production

Genetic stability improvements:

• Homologous recombination methods for stable integration without antibiotic selection

• Long-term stability of expression has been demonstrated through serial transfer experiments (up to 70 transfers, equivalent to 700 generations)

Co-expression strategies:

• Simultaneous expression of multiple bacteriocins with complementary activities

• Successful co-expression of nisin Z and leucocin C in L. lactis has been achieved, resulting in enhanced antimicrobial activity

Secretion efficiency enhancements:

• Optimization of signal sequences for specific hosts

• Co-expression with appropriate transport machinery

• For example, using the ABC transporter and accessory protein encoded by lecXTS genes for efficient secretion

What are the common technical challenges in purifying active recombinant leucocin C?

Researchers often encounter several challenges during purification of recombinant leucocin C:

Activity loss during purification:

• Bacteriocins may adhere to laboratory plasticware due to their hydrophobic nature

• Solution: Use glass or low-binding plastics; include low concentrations of Tween-20 or Triton X-100 in buffers

Multiple conformational states:

• Incorrect disulfide bond formation can lead to multiple conformational states

• Solution: Co-expression with appropriate accessory proteins or chaperones that ensure correct disulfide bonding

Low yields:

• Expression levels may be insufficient for detailed characterization

• Solution: Optimize fermentation conditions; consider low oxygen levels for certain bacteriocins

Verification of activity:

• Ensuring that purified recombinant leucocin C retains full biological activity

• Solution: Compare antimicrobial activity with commercial or natural bacteriocins; use multiple indicator strains

Interference from media components:

• Complex media components may co-purify with bacteriocins

• Solution: Use defined minimal media for production when possible; employ multiple purification steps

How can researchers accurately determine the antimicrobial spectrum of recombinant leucocin C?

Determining the antimicrobial spectrum of recombinant leucocin C requires systematic evaluation using multiple methodologies:

Agar diffusion assays:

• Spot-on-lawn technique using multiple indicator strains

• Well diffusion assays with standardized amounts of purified bacteriocin

• Critical to maintain consistent conditions (agar depth, inoculum density, etc.)

Broth microdilution assays:

• Determination of minimum inhibitory concentrations (MICs)

• Determination of minimum bactericidal concentrations (MBCs)

• Serial dilutions of purified bacteriocin with standardized inoculum of test organisms

Time-kill kinetics:

• Assessment of bactericidal versus bacteriostatic activity

• Monitoring bacterial viability over time using colony counts

• Applied in practical settings like pasteurized milk to verify effectiveness

Resistant mutant generation:

• Selection of resistant variants through repeated exposure

• Characterization of resistance mechanisms

• Cross-resistance testing with other bacteriocins

A comprehensive panel of test organisms should include:

• Primary targets (e.g., Listeria monocytogenes strains)

• Other Gram-positive bacteria

• Selected Gram-negative bacteria

• Related lactic acid bacteria

• Potential probiotic strains

• Food spoilage organisms

What emerging applications exist for recombinant leucocin C beyond food preservation?

While food preservation remains the primary application, recombinant leucocin C shows potential in several emerging areas:

Therapeutic delivery systems:

• Using probiotic organisms like S. boulardii expressing leucocin C for targeted delivery in the gastrointestinal tract

• Potential applications in treating infections caused by susceptible pathogens

• S. boulardii's ability to survive in stomach and intestine makes it an attractive delivery vehicle

Combination with other therapeutic modalities:

• Potential synergy with conventional antibiotics

• Combination with prebiotics or other bioactive compounds

Biofilm control:

• Investigation of activity against biofilms formed by Listeria and other pathogens

• Potential applications in medical device coatings or sanitation

Development of novel antimicrobial peptides:

• Structure-guided design of synthetic peptides based on leucocin C

• Creation of hybrid bacteriocins with enhanced stability or broader activity spectrum

Microbiome modulation:

• Selective inhibition of specific microbial populations

• Potential applications in microbiome research and intervention strategies

How might CRISPR-Cas9 and other gene editing tools advance recombinant bacteriocin research?

CRISPR-Cas9 and other advanced gene editing tools offer exciting possibilities for bacteriocin research:

Improved host strain development:

• Precise deletion of undesired genes (proteases, competing metabolic pathways)

• Introduction of multiple modifications to optimize bacteriocin production

• Engineering of the host's metabolic pathways to enhance precursor availability

Structure-function studies:

• Systematic modification of bacteriocin genes to create libraries of variants

• High-throughput screening for variants with enhanced activity or stability

• Identification of critical residues for receptor binding and antimicrobial activity

Multiplexed bacteriocin expression:

• Engineering strains to produce multiple bacteriocins simultaneously

• Fine-tuning expression levels of each bacteriocin to achieve optimal antimicrobial activity

• Integrating regulatory elements for controlled expression

In situ modification of microbiomes:

• Development of engineered bacteriocin-producing strains for specific ecological niches

• Targeted elimination of pathogens while preserving beneficial microbiota

Genetic circuit design:

• Creation of synthetic genetic circuits for regulated bacteriocin production

• Sensing-and-responding systems that produce bacteriocins only in the presence of specific pathogens or environmental signals

These advanced genetic tools could significantly accelerate the development of next-generation bacteriocin-based antimicrobials with enhanced properties and precise activity spectra.